China (Mainland)
Premiumsupplier
Factory Sale Strong Effect Anti Diabetes Drug CAS 864070-44-0 Empagliflozin CAS NO.864070-44-0
- Min.Order: 10 Gram
- Payment Terms: T/T,
- Product Details
Keywords
- 99% Empagliflozin
- Pharmaceutical Raw Materials
- API Manufacturer
Quick Details
- ProName: Factory Sale Strong Effect Anti Diabet...
- CasNo: 864070-44-0
- Molecular Formula: C23H27ClO7
- Appearance: White Powder
- Application: It Can Be Used As Pharmaceutical Inte...
- DeliveryTime: 2-4 days after confirming your payment...
- PackAge: 100g/ bag, 2 kg/ bag, 25kg/ carton or ...
- Port: Wuhan
- ProductionCapacity: 10000 Metric Ton/Month
- Purity: 99%
- Storage: Store in sealed containers at cool & d...
- Transportation: By DHL, TNT, FedEx, HKEMS, UPS, Etc
- LimitNum: 10 Gram
Superiority
Advantages:
Hubei XinRunde Chemical Co., Ltd is a renowned pharmaceutical manufacturer. We can offer high quality products at competitive price in quick delivery with 100% custom pass guaranteed. Never stop striving to offer our best service is our philosophy. We have Flexible and Untraceable payment terms. As a leading manufacture, our products have been exported to Germany, Norway, Poland, Finland, Spain, UK, France, Russia, USA, Brazil, Mexico, Australia, Japan, Korea, Thailand, Indonesia, Uruguay and many other countries.
1. Quality.Every batch of steroid powders have tobetested by our QC(quality control) before they are allowed to sell.
2. Delivery We have stock, so we can delivery quickly at the very day when receive the payment. Within 24 hours after receiving the payment Lead time 4 or 7 days.
3. Discreet package Safelyand Professionally Disguised Package Guaranteed. For your safety and to insure delivery all products will be packed in a discreet way to prevent any suspicions, no steroids related name will appear on the parcels. high successful delivery rate.
4. Warm after-sale service Any of your question would be solved for the first as soon as possible.
Details
Empagliflozin Description
Empagliflozin (trade name Jardiance) is a drug of the gliflozin class, approved for the treatment of type 2 diabetes in adults in 2014. It was developed by Boehringer Ingelheim and Eli Lilly and Company.
Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and causes sugar in the blood to be excreted by the kidneys and eliminated in urine.
Empagliflozin is a potent SGLT-2 inhibitor and has a high degree of selectivity over SGLT-1, 4, 5 and 6 than other reported SGLT-2 inhibitors. When tested with a panel of human cell lines over-expressed SGLT-1, 2, 4, 5 and 6,
Empagliflozin treatment competitively bind to SGLT-2 over glucose at low dose .
In human proximal tublular cell (PTC) cell line HK2 cells, Empagliflozin treatment for 72 h inhibits the expression of SGLT-2 which in turn reversed high glucose induced TLR4 expression, NF-κB binding, IL-6 secretion, AP-1 binding and CIV expression .
Empagliflozin Basic Information
| Name | Empagliflozin |
| Synonyms | BI 10773; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol |
| Molecular Formula | C23H27ClO7 |
| Molecular Weight | 450.91 |
| CAS Registry Number | 864070-44-0 |
|
|
||